Breaking Down Biosims: Lower Costs, Better Care

Breaking Down Biosims: What They Are and How Dart-Care Is Expanding Access to Affordable Care

In the world of specialty medications, the term “biosimilars” (or “biosims”) is gaining more attention—and for good reason. These innovative therapies are creating new pathways to treatment for patients across the country. At Dart-Care, we’re proud to support greater access to biosims through affordable pricing, exceptional service, and seamless care coordination.

What Are Biosimilars?

Biosimilars are biologic medicines that are highly similar to already-approved reference biologics. These aren’t generic drugs—they’re made from living organisms and are carefully developed to match the reference product in safety, effectiveness, and clinical performance.

Because biologics are complex, biosimilars go through rigorous testing to ensure they deliver the same benefits without clinically meaningful differences. The FDA has a strict approval process for biosimilars, ensuring that patients and providers can trust in their quality and outcomes.

💡 Why Biosimilars Matter

Biosimilars are helping reshape the healthcare landscape by:

• 💰 Lowering Costs: Biosims often come at a significantly lower price than the original biologic drugs, driving down healthcare costs for patients, employers, and health systems.
• 🚪 Increasing Access: With reduced financial barriers, more patients can access life-changing therapies for chronic and complex conditions like cancer, rheumatoid arthritis, and multiple sclerosis.
• 💡 Promoting Innovation: The biosimilar market encourages competition, which leads to better pricing strategies and more treatment options.

🩺Dart-Care: Making Biosimilars Work for Patients

At Dart-Care, we believe every patient deserves access to high-quality, affordable specialty medications—and biosimilars are a key part of that vision. Here’s how we’re making a difference:

• 💸 Affordable Access: Through direct relationships, transparent pricing models, and strategic distribution, we help patients receive the biosims they need at a fraction of the typical cost.
• 🤝 Outstanding Service: Our team provides white-glove service at every step, from benefits verification and prior authorization to delivery and ongoing support.
• 🔗 Coordinated Care: We work hand-in-hand with providers, infusion centers, home health partners, and payers to ensure each patient receives their treatment with zero disruption and full transparency.

As of May 2025, the FDA has approved over 60 biosimilar products across various therapeutic areas. Here’s a selection of these biosimilars:

• Adalimumab (Humira) Biosimilars:
  • Amjevita (adalimumab-atto)
  • Cyltezo (adalimumab-adbm)
  • Hyrimoz (adalimumab-adaz)
  • Yuflyma (adalimumab-aaty)
  • Simlandi (adalimumab-ryvk)
• Bevacizumab (Avastin) Biosimilars:
  • Mvasi (bevacizumab-awwb)
  • Zirabev (bevacizumab-bvzr)
  • Jobevne (bevacizumab-nwgd)
• Trastuzumab (Herceptin) Biosimilars:
  • Ogivri (trastuzumab-dkst)
  • Herzuma (trastuzumab-pkrb)
  • Trazimera (trastuzumab-qyyp)
• Infliximab (Remicade) Biosimilars:
  • Inflectra (infliximab-dyyb)
  • Renflexis (infliximab-abda)
  • Ixifi (infliximab-qbtx)
• Etanercept (Enbrel) Biosimilars:
  • Erelzi (etanercept-szzs)
  • Eticovo (etanercept-ykro)
• Pegfilgrastim (Neulasta) Biosimilars:
  • Fulphila (pegfilgrastim-jmdb)
  • Udenyca (pegfilgrastim-cbqv)
  • Ziextenzo (pegfilgrastim-bmez)
• Filgrastim (Neupogen) Biosimilars:
  • Zarxio (filgrastim-sndz)
  • Nivestym (filgrastim-aafi)
• Epoetin Alfa (Epogen/Procrit) Biosimilar:
  • Retacrit (epoetin alfa-epbx)
• Insulin Glargine (Lantus) Biosimilars:
  • Semglee (insulin glargine-yfgn)
  • Rezvoglar (insulin glargine-aglr)
• Ranibizumab (Lucentis) Biosimilars:
  • Byooviz (ranibizumab-nuna)
  • Cimerli (ranibizumab-eqrn)
• Ustekinumab (Stelara) Biosimilars:
  • Pyzchiva (ustekinumab-ttwe)
  • Otulfi (ustekinumab-aauz)
  • Imuldosa (ustekinumab-srlf)
• Aflibercept (Eylea) Biosimilars:
  • Ahzantive (aflibercept-mrbb)
  • Enzeevu (aflibercept-abzv)
  • Pavblu (aflibercept-ayyh)
• Denosumab (Prolia/Xgeva) Biosimilars:
  • Bomyntra (denosumab-bnht)
  • Conexxence (denosumab-bnht)
  • Osenvelt (denosumab-bmwo)
  • Stoboclo (denosumab-bmwo)

For the most up-to-date information on FDA-approved biosimilars, you can refer to the FDA’s Biosimilar Product Information page or the Purple Book Database.

A Smarter Way Forward

Biosimilars represent a smarter, more sustainable way to deliver specialty care—and Dart-Care is leading the way in bringing those benefits to real people. By combining cost savings with exceptional service and coordinated care, we’re not just delivering medicine—we’re delivering peace of mind.